Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy
from Rx for Biotech Hosted by Podcast Host Christopher Leidli
In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.
Embed this episode
No transcript yet.